TY - JOUR AU - Roach, M. AU - Bae, K. AU - Speight, J. PY - 2008 DA - 2008// TI - Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.9881 DO - 10.1200/JCO.2007.13.9881 ID - Roach2008 ER - TY - JOUR AU - D’Amico, A. V. AU - Manola, J. AU - Loffredo, M. PY - 2004 DA - 2004// TI - Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JO - JAMA VL - 292 UR - https://doi.org/10.1001/jama.292.7.821 DO - 10.1001/jama.292.7.821 ID - D’Amico2004 ER - TY - JOUR AU - Bolla, M. AU - Tienhoven, G. AU - Warde, P. PY - 2010 DA - 2010// TI - External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(10)70223-0 DO - 10.1016/S1470-2045(10)70223-0 ID - Bolla2010 ER - TY - JOUR AU - Tseng, Y. D. AU - Chen, M. AU - Beard, C. AU - Martin, N. AU - Orio, P. F. AU - Loffredo, M. PY - 2012 DA - 2012// TI - Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all-cause mortality JO - J Urol VL - 187 UR - https://doi.org/10.1016/j.juro.2012.01.073 DO - 10.1016/j.juro.2012.01.073 ID - Tseng2012 ER - TY - JOUR AU - Foo, M. AU - Lavieri, M. AU - Pickles, T. PY - 2013 DA - 2013// TI - Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database JO - Int J Radiat Oncol Biol Phys VL - 85 UR - https://doi.org/10.1016/j.ijrobp.2012.04.009 DO - 10.1016/j.ijrobp.2012.04.009 ID - Foo2013 ER - TY - JOUR AU - Malik, R. AU - Jani, A. B. AU - Liauw, S. L. PY - 2011 DA - 2011// TI - Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer JO - Int J Radiat Oncol Biol Phys VL - 79 UR - https://doi.org/10.1016/j.ijrobp.2009.12.029 DO - 10.1016/j.ijrobp.2009.12.029 ID - Malik2011 ER - TY - STD TI - Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer.J Urol. 1996:156 (2):450–3. ID - ref7 ER - TY - JOUR AU - Ray, M. E. AU - Thames, H. D. AU - Levy, L. B. AU - Horwitz, E. M. AU - Kupelian, P. A. AU - Martinez, A. A. AU - Kuban, D. A. PY - 2006 DA - 2006// TI - PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis JO - Int J Radiat Oncol Biol Phys VL - 64 UR - https://doi.org/10.1016/j.ijrobp.2005.07.006 DO - 10.1016/j.ijrobp.2005.07.006 ID - Ray2006 ER - TY - JOUR AU - Alcántara, P. AU - Hanlon, A. AU - Buyyounouski, M. K. AU - Horwitz, E. M. AU - Pollack, A. PY - 2007 DA - 2007// TI - Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22341 DO - 10.1002/cncr.22341 ID - Alcántara2007 ER - TY - JOUR AU - Zelefsky, M. J. AU - Shi, W. AU - Yamada, Y. AU - Kollmeier, M. A. AU - Cox, B. AU - Park, J. AU - Seshan, V. E. PY - 2009 DA - 2009// TI - Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality JO - Int J Radiat Oncol Biol Phys VL - 75 UR - https://doi.org/10.1016/j.ijrobp.2008.12.067 DO - 10.1016/j.ijrobp.2008.12.067 ID - Zelefsky2009 ER - TY - JOUR AU - D'amico, A. V. AU - Chen, M. AU - Castro, M. D. AU - Loffredo, M. AU - Lamb, D. S. AU - Steigler, A. AU - Denham, J. W. PY - 2012 DA - 2012// TI - Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(11)70295-9 DO - 10.1016/S1470-2045(11)70295-9 ID - D'amico2012 ER - TY - STD TI - Son CH, Hamstra DA, Feng FY, Liauw SL. High-risk prostate cancer treated with dose-escalated RT: an analysis of hormonal therapy use and duration, and prognostic implications of PSA nadir 0.2 to select men for short-term hormonal therapy. Am J Clin Oncol. 2014:40(4):348-52. ID - ref12 ER - TY - JOUR AU - Roach, M. AU - Hanks, G. AU - Thames, H. PY - 2006 DA - 2006// TI - Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference JO - Int J Radiat Oncol Biol Phys VL - 65 UR - https://doi.org/10.1016/j.ijrobp.2006.04.029 DO - 10.1016/j.ijrobp.2006.04.029 ID - Roach2006 ER - TY - JOUR AU - Cox, J. D. AU - Stetz, J. AU - Pajak, T. F. PY - 1995 DA - 1995// TI - Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) JO - Int J Radiat Oncol Biol Phys VL - 31 UR - https://doi.org/10.1016/0360-3016(95)00060-C DO - 10.1016/0360-3016(95)00060-C ID - Cox1995 ER - TY - JOUR AU - Johnson, S. B. AU - Jackson, W. C. AU - Murgic, J. AU - Feng, F. Y. AU - Hamstra, D. A. PY - 2015 DA - 2015// TI - Time to nadir PSA: of popes and PSA--the immortality bias JO - Am J Clin Oncol VL - 38 UR - https://doi.org/10.1097/COC.0b013e3182a468b2 DO - 10.1097/COC.0b013e3182a468b2 ID - Johnson2015 ER - TY - JOUR AU - Critz, F. A. AU - Levinson, A. K. AU - Williams, W. H. AU - Holladay, D. A. AU - Holladay, C. T. PY - 1997 DA - 1997// TI - The PSA nadir that indicates potential cure after radiotherapy for prostate cancer JO - Urology VL - 49 UR - https://doi.org/10.1016/S0090-4295(96)00666-8 DO - 10.1016/S0090-4295(96)00666-8 ID - Critz1997 ER - TY - JOUR AU - Cury, F. L. AU - Hunt, D. AU - Roach, M. AU - Shipley, W. AU - Gore, E. AU - Hsu, I. C. PY - 2013 DA - 2013// TI - Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413 JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.28019 DO - 10.1002/cncr.28019 ID - Cury2013 ER - TY - STD TI - Mohler JL, Armstrong AJ, Bahnson RR et al. Prostate cancer, version 1.2016. J Natl Compr Cancer Netw. 2016;14(1):19–30. ID - ref18 ER - TY - JOUR AU - Dubray, B. M. AU - Beckendorf, V. AU - Guerif, S. AU - Prise, E. AU - Reynaud-Bougnoux, A. AU - Hannoun Levi, J. M. PY - 2011 DA - 2011// TI - Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer- intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741) JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.4521 DO - 10.1200/jco.2011.29.15_suppl.4521 ID - Dubray2011 ER - TY - JOUR AU - Nabid, A. AU - Carrier, N. AU - Vigneault, E. AU - Souhami, L. AU - Lemaire, C. AU - Brassard, M. PY - 2015 DA - 2015// TI - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: a phase III trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/jco.2015.33.7_suppl.5 DO - 10.1200/jco.2015.33.7_suppl.5 ID - Nabid2015 ER - TY - JOUR AU - Bolla, M. AU - Maingon, P. AU - Carrie, C. AU - Villa, S. AU - Kitsios, P. AU - Poortmans, P. PY - 2016 DA - 2016// TI - Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991 JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8055 DO - 10.1200/JCO.2015.64.8055 ID - Bolla2016 ER - TY - JOUR AU - Zelefsky, M. J. AU - Gomez, D. R. AU - Polkinghorn, W. R. AU - Pei, X. AU - Kollmeier, M. PY - 2013 DA - 2013// TI - Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes JO - Int J Radiat Oncol Biol Phys VL - 86 UR - https://doi.org/10.1016/j.ijrobp.2013.02.004 DO - 10.1016/j.ijrobp.2013.02.004 ID - Zelefsky2013 ER - TY - JOUR AU - Zilli, T. AU - Dal Pra, A. AU - Kountouri, M. AU - Miralbell, R. PY - 2016 DA - 2016// TI - Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: a systematic review of the literature JO - Cancer Treat Rev VL - 46 UR - https://doi.org/10.1016/j.ctrv.2016.03.016 DO - 10.1016/j.ctrv.2016.03.016 ID - Zilli2016 ER - TY - JOUR AU - McGuire, S. E. AU - Lee, A. K. AU - Cerne, J. Z. AU - Munsell, M. F. AU - Levy, L. B. AU - Kudchadker, R. J. PY - 2013 DA - 2013// TI - PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose- escalated radiation therapy era JO - Int J Radiat Oncol Biol Phys VL - 85 UR - https://doi.org/10.1016/j.ijrobp.2012.08.036 DO - 10.1016/j.ijrobp.2012.08.036 ID - McGuire2013 ER -